Peter Vermeul’s Post
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchTHCCBDHempSafetyNeurologyMental Health Why This Matters Clinicians need to understand that cannabis effects…
Symptoms improve for cancer patients after cannabis extract use, study finds – leafie
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerResearchCBDTHCPainAnxietySafety Why This Matters # Clinical SignificanceCancer patients experiencing…
Review Finds Just 31% of Consumer CBD Products Meet Label-Accuracy Standard
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDSafetyIndustryResearchPolicyHempDosing Why This Matters Clinicians prescribing or recommending CBD to patients face a…
The CB2 receptor, key in resistance to trastuzumab – Demócrata
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerResearchCBDNeurologyMental HealthSafetyAging Why This Matters This research identifying CB2 receptor involvement in…
CED Cannabis Science Digest: 3 Behavior and Safety Signals Worth Watching
No fresh human clinical-trial-level cannabis paper cleared the lead threshold on June 19, 2026, but three verified cannabis behavior safety signals were still worth preserving. These signals include stigma related to cannabis use disorder, driving…
How Medical Marijuana Recommendations Expand Care
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyPainAnxietyMental HealthSafetyIndustryResearch Why This Matters Clinicians need to understand their role in the…
What’s in My Weed?
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyCBDTHCHempIndustryDosing Clinical Summary This article examines the results of laboratory testing for…
PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyMental HealthAnxietyNeurologyDosingIndustry Why This Matters This Phase 3 trial represents the first…
CED Cannabis Science Digest: 3 Safety Signals Worth Watching
This digest highlights prenatal cannabis safety signals verified in 2026, focusing on exposure risks, inflammatory bowel disease evidence, and semisynthetic cannabinoids. These signals provide important counseling insights without overstating treatment…
Ohio Tax Department Amends Adult-Use Cannabis Tax Rules
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryResearchSafetyHempTHCCBD Why This Matters Ohio’s tax amendments directly affect the cost and…
